IN8bio Stock
IN8bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- William T.
- Employees
- 18
- Market cap
- $11 M
- IPO
- 30/07/2021
- Web
- in8bio.com
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell…
IN8bio stock: price history
1D
-6.7%
1W
-17.2%
1M
+9.9%
6M
-22.9%
YTD
-52.6%
1Y
-47.4%
2Y
-83.8%
5Y
-99.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~22% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about IN8bio
Analyst assessment of IN8bio
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 13/03/2026
IN8bio stock metrics
P/E
-0.59
P/B
1.18
EV/EBITDA
0.29
RETURN ON EQUITY
-26.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.9%
FLOAT SHARES
7,182,029
AVG. DAILY VOLUME (30D)
45,188
Insider transactions (SEC)
FAIRBAIRN EMILY
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about IN8bio stock
What does IN8bio do?
IN8bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is William T., the company employs around 18 people.
The IPO was on 30/07/2021; the stock trades on NASDAQ under the ticker INAB.
What do analysts say about IN8bio stock?
4 analysts rate the stock, the consensus is Buy (as of 13/03/2026).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does IN8bio report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does IN8bio pay a dividend?
No, IN8bio currently does not pay a dividend.
Which stocks are comparable to IN8bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get IN8bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess IN8bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.